The Virtual Reality Room
Targeting Type 2 Inflammation in Atopic Diseases: The Role of Interleukin Inhibitors
William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary and Critical Care Medicine
University of Wisconsin School of Medicine and Public Health
This online activity is focused on the team involved in the management of patients with type 2 inflammation in atopic diseases.
This activity is intended for U.S.-based pulmonologists, allergists, immunologists, otolaryngologists, pediatric/adolescent dermatologists, and other primary health care professionals (physicians, physician assistants, nurse practitioners) involved in the management of patients with atopic diseases including asthma, CRSwNP, and AD.
After completing the CME activity, learners should be better able to:
- Describe the Th2 inflammatory pathways and cascades underlying the pathophysiology of atopic diseases including asthma, CRSwNP, and AD
- Review the clinical profiles and mechanisms of action of interleukin inhibitors used for the treatment of atopic diseases including asthma, CRSwNP, and AD
- Develop treatment plans for patients with atopic diseases including asthma, CRSwNP, and AD based on patient-specific factors relevant to clinical decision making
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this web-based activity for a maximum of 1.5 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the treatment and management of patients with DR.
CNE Credits: 1.5 ANCC Contact Hours.
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
William W. Busse, MD received consulting fees from Sanofi, Regeneron, AstraZeneca, GlaxoSmithKline, Genentech, Novartis. He serves on the Speakers Bureau for Regeneron, received royalty from Elsevier, and served on the Data Safety Monitoring Board for Boston Scientific.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Diana Tommasi, Director of Medical and Scientific Services, has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE
credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: March 11, 2020
EXPIRATION DATE: March 11, 2021